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Abstract
Cardiac re-transplantation (ReTx) accounts for a small proportion of the patients under-
going heart transplantation every year. However, due to improved patient management 
following transplant, the number of patients potentially requiring re-transplant is grow-
ing. We will review the current epidemiology of ReTx and describe the potential increase 
in candidates for ReTx. We will also highlight important characteristics of patients 
undergoing ReTx including co-morbidities and allosensitization. We will summarize 
single-center and registry data on patient outcomes following ReTx, and discuss patient 
selection. Finally, we will outline the management of patients following cardiac ReTx as 
well as alternate therapies and ethical considerations in cardiac ReTx.
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1. Introduction
There are over 5000 heart transplants performed annually worldwide. Survival following 
cardiac transplantation has improved dramatically, with one-year survival approaching 85% 
with a median survival of 11 years [1]. As a result, many patients are now surviving to develop 
late complications of cardiac transplantation such as chronic rejection, cardiac allograft vas-
culopathy (CAV), or late graft failure. Unfortunately, there are few medical therapies that 
significantly alter the development and progression of these complications, particularly at 
advanced stages [2, 3]. Cardiac retransplantation (ReTx) offers possible benefit to patients 
who survive to develop these late complications, particularly those patients who have devel-
oped left ventricular systolic dysfunction [4].
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
The first ReTx was performed in 1974 at Stanford, and the first group of patients was reported 
in 1977 by Copeland et al., which included 5 patients who underwent ReTx for either CAV or 
acute graft failure. ReTx currently comprises 3.0% of adult cardiac transplants [3, 5, 6], and a 
similar proportion of pediatric transplants [7]. While this proportion may seem small, it mirrors 
the proportion of patients transplanted for congenital heart disease, hypertrophic cardiomy-
opathy, restrictive cardiomyopathy, and valvulvar cardiomyopathy [5]. Additionally, as more 
patients survive to develop late complications, the number of patients who are candidates for 
ReTx will rise. Given this increase, ReTx will potentially outgrow these other indications for 
cardiac transplant.
2. Epidemiology of cardiac re-transplantation
The number of patients undergoing ReTx has been gradually increasing over time. Between 
2000 and 2005, ReTx accounted for 2.9% of all heart transplants [3]. Between January 2009 
and June 2015 there were 722 patients who underwent ReTx, which constituted 3.1% of heart 
transplants. While this seems like a small increase over time, there has been a simultaneous 
shift towards more rigorous patient selection for ReTx. This shift has been a response to the 
uniformly poor outcomes when patients undergo ReTx for acute events like primary graft 
failure. In this context, the median survival of patients undergoing cardiac transplantation has 
increased from 8.5 years in the era of 1982–1991 to almost 12 years for patients transplanted 
between 2002 and 2008. Median survival is even longer in young patients, with a median sur-
vival of 12.6 years in patients undergoing initial transplant between age 18 and 39, compared 
to 9.1 years in patients aged 60–69. Patients under age 40 comprise 17% of the adult heart 
transplant population, but also represent the population most likely to require to eventually 
require ReTx. There is no reason to believe that there will not be an ongoing trend towards 
improved survival, potentially increasing the number of patients considered for ReTx.
Most of the data regarding the epidemiology of ReTx is only reflective of patients who success-
fully undergo ReTx. Therefore, in order to demonstrate the potential increase in candidates 
for ReTx, we have provided an estimate based on outcomes in current transplant recipients, 
shown in Figure 1. Currently 74% of patients are surviving at least 5 years after their initial 
transplant date [5]. We will assume that patients who die before this time are not candidates 
for ReTx given poor outcomes in patients undergoing ReTx for acute graft failure. The pro-
portion of patients who are over age 60 at the time of initial cardiac transplant is 23.8% [5]. 
For the sake of a conservative estimate, we will assume that these patients are not candidates 
for ReTx due to advanced age. In patients who die more than 5 years after transplant, CAV 
accounts for 7–17% of deaths and graft dysfunction accounts for 22–40% of deaths [5]. If all 
patients under age 60 at initial transplant who eventually die from CAV or graft dysfunction 
are assessed for ReTx, then 17% of all transplant patients could potentially be ReTx eligible. 
There are several assumptions built into this estimate. Many patients who are potential ReTx 
candidates due to CAV will not be eligible due to sudden death [8], or co-morbidities that 
preclude ReTx. However, if even half of the patients we estimated undergo ReTx this would 
essentially triple the current rate of ReTx.
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3. Characteristics of cardiac re-transplant recipients
Patients who undergo ReTx have characteristics distinct from those undergoing initial 
transplant. Some of these characteristics are related to procedures and immunosuppression 
required for the initial cardiac transplant. Meanwhile, other characteristics are related to sur-
viving long enough to be considered for ReTx. However, as noted previously, this data only 
Figure 1. Estimate of the number of patients who may be candidates for cardiac ReTx. Estimates are based on ISHLT 
registry data [5, 9].
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reflects patients who have successfully undergone ReTx. The group of patients who may be 
considered candidates are likely older with more medical co-morbidities.
Many characteristics of patients undergoing ReTx are associated with better outcomes, and 
generally reflect being young and healthy enough to be considered for a second operation. 
ReTx patients are younger compared to patients undergoing initial cardiac transplant, 
with a mean age of 46 years compared to 54 years in the ISHLT database [9]. Amiodarone 
exposure at any time point is also less frequent in patients undergoing ReTx, occurring in 
10% of patients compared to 32% of initial transplant recipients [9]. This is interesting in 
light of emerging evidence suggesting amiodarone use is associated with higher 1-year 
mortality after transplant [10]. This finding is likely due to the low incidence of atrial and 
ventricular arrhythmias in the transplant population [11]. Finally, patients undergoing 
ReTx have lower pulmonary vascular resistance compared to other indications for trans-
plant [5]. Overall these characteristics reflect the selection bias inherent in selection of 
ReTx candidates.
In ReTx populations, the characteristics that predict improved survival after cardiac trans-
plant are more than outweighed by characteristics associated with adverse outcomes. Most 
patients undergoing ReTx have been exposed to calcineurin inhibitors after the initial cardiac 
transplant. As a consequence, they are more likely to have hypertension and renal dysfunc-
tion. In the ISHLT database 15.6% of patients undergoing ReTx had received prior dialysis 
compared to 3.9% in patients undergoing initial transplant [9]. Baseline creatinine was also 
higher in the ReTx group, 1.6 mg/dl compared to 1.2 mg/dL in initial transplant patients [9]. 
Hypertension is present in 57% of ReTx compared to 46% of initial transplant patients [9]. 
Additionally, ReTx patients have been exposed to a previous allograft and blood products 
during the initial cardiac transplant. Due to previous exposures, patients undergoing ReTx 
are more likely to be sensitized or highly sensitized. Almost 10% of patients undergoing ReTx 
have a Panel of Reactive Antibodies (PRA) greater than 80% compared to 2% of the primary 
transplant group [9]. Conversely, less than 50% of ReTx patients have a PRA of 0 compared 
to 65% of initial transplant patients [9]. High degrees of sensitization may complicate ReTx, 
requiring desensitization treatments prior to transplant or more aggressive induction therapy 
after transplant. All patients undergoing ReTx have had a prior sternotomy, which increases 
operative mortality as well as increasing cardiopulmonary bypass time, which increases mor-
bidity and 90 day mortality associated with the operation [12, 13]. Finally, patients undergo-
ing ReTx are more likely to be hospitalized at time of transplant, with 52% of ReTx patients 
admitted at the time of transplant compared to 44% of initial transplant patients [9]. This may 
reflect a trigger point for considering ReTx. These factors highlight the high risk nature of the 
ReTx population.
The characteristics outlined above reflect the population of patients who successfully undergo 
ReTx. The broader population of patients who may have been considered candidates for ReTx 
includes patients who may be too old, have co-morbidities that result in prohibitive risk, or 
are too highly sensitized to be successfully matched for ReTx. This suggests that, overall, the 
population considered for ReTx will be at significantly higher risk for peri-operative, short-
term, and long-term complications after transplantation.
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4. Patient outcomes following cardiac re-transplantation
There have been several attempts to characterize outcomes after ReTx. These studies span sev-
eral eras of transplant management and reflect temoporal changes in patient selection criteria. 
What follows is not a comprehensive review of the available evidence, but a selected group of 
studies to highlight important concepts in the outcomes after ReTx.
4.1. Single-center studies
There have been several single-center studies outlining outcomes following ReTx, out-
lined in Table 1. Stanford reported a cohort of 66 patients who underwent ReTx before 
1994 [14]. They found decreased one-year survival compared to primary heart transplant 
recipients (55 compared to 81%), with better survival in patients undergoing ReTx for CAV 
[14]. Schnetzler et al. investigated 24 patients who underwent ReTx before 1996 and found 
significantly reduced one-year survival for patient undergoing ReTx within a year (27.3%) 
compared to those undergoing ReTx after more than 1 year (61.5%) [15]. The patients trans-
planted within 1 year were exclusively patients with primary graft failure or intractable 
rejection [15]. A group from Columbia described a cohort of 43 patients undergoing ReTx 
before 1997 where 1-year and 5-year survival were decreased (66 vs. 76% and 51 vs. 60%) 
compared to initial transplant recipients [16]. They found that a shorter interval between 
ReTx and initial transplant as well as initial transplant for ischemic cardiomyopathy were 
associated with increased mortality compared to patients without those factors [16]. They 
Author Year Center Patients Results
Smith 1995 Stanford 66 (26 acute, 40 chronic) 1-year survival 55% (vs 81%), 5-year 
survival 33% (vs 62%)
Schnetzler 1998 Paris 24 (11 acute, 13 chronic) 1-year survival 45.5% (vs. 71.6%), 5-year 
survival 31.2% (vs. 63.4%)
John 1999 Columbia 43 (13 within 2 years, 30 
after 2 years)
1-year survival 66% (vs 76%), 5-year 
survival 51% (vs. 60%).
Schlechta 2001 Vienna 31 (16 acute, 15 chronic) 1-year survival 48.2% (vs. 80.2%), 5-year 
survival 36.8% (vs. 66.6%)
Topkara 2005 Columbia 41 patients 1-year survival 72.2% (vs. 85.5%), 5-year 
survival 47.5 (vs. 72.9%)
Alturi 2008 Pennsylvania 15 patients (11 chronic, 
4 acute)
1-year survival 86.6% (vs 90.9%), 5-year 
survival 71.4% (vs. 79.1%)
Goerler 2008 Hannover 41 (18 acute, 23 chronic) 1-year survival 64% (vs. 83%), 5-year 
survival 47% (vs 72%)
Saito 2013 London, 
Ontario
22 (12 acute, 10 chronic) Conditional 1-year survival 93.3% (vs. 
93.0%) if surviving 30 days
Table 1. Single-center studies of re-transplant survival.
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hypothesized that patients with ischemic cardiomyopathy may have atherosclerotic disease 
in other vascular beds leading to worse outcomes [16]. They also found improved survival 
in their population after excluding patients with acute graft failure and significant renal 
dysfunction [16]. A cohort of patients undergoing ReTx between 1984 and 1999 from Vienna 
had one-year survival as low as 48.2% in a cohort that was almost evenly split between acute 
and chronic indications for ReTx [17]. The authors suggested younger age, lack of peripheral 
vascular disease, and ability to actively rehabilitate after the primary transplant as criteria 
for ReTx candidacy [17]. These early studies were essential to identify the factors that influ-
ence survival, leading to better patient outcomes.
More contemporary cohorts have shown some improvement in ReTx outcomes through 
more rigorous patient selection. A single-center study from Germany reported a cohort of 
41 patients who underwent ReTx prior to July 2006 [18]. Of those patients 18 underwent 
ReTx for acute graft failure and 23 for chronic graft failure [18]. They found decreased 1-year 
(64 compared to 83%) and 5-year survival (47 compared to 72%) in patients undergoing 
ReTx compared to initial transplant [18]. This finding was driven by high 30-day mortal-
ity (34.1 vs. 9.5%) in patients undergoing ReTx [18]. In their cohort, patients with chronic 
graft failure had better survival than those with acute graft failure as an indication for ReTx 
[18]. In a smaller Canadian study including patients transplanted bettween 1981 and 2011, 
patients who were retransplanted more than 1 year after initial implant had similar survival 
as patients undergoing initial transplantation [19]. Columbia reported improved survival in 
patients transplanted between 1992 and 2002 after selecting groups of patients with mostly 
CAV as the indication for ReTx [20]. The University of Pennsylvania heart transplant pro-
gram had a similar experience in patients undergoing ReTx between 1987 and 2007 [20, 21]. 
While survival following ReTx is still lower compared to initial transplant patients, further 
improvements in patient selection may continue to decrease this disparity.
4.2. Registry studies
Survival after cardiac retransplantation has also been assessed using registry data, outlined 
in Table 2. An analysis from the International Society of Heart and Lung Transplant (ISHLT) 
database identified a total of 514 patients undergoing ReTx between 1987 and 1998, of whom 
more than 50% underwent ReTx for CAV. [22]. In this population, one-year survival was only 
65%, but was higher after excluding patients who underwent ReTx within 2 years of the initial 
transplant [22]. However, post-transplant survival remained inferior in the subset of patients 
undergoing ReTx for chronic graft failure compared to patients undergoing initial transplant 
[22]. Patients undergoing ReTx at a low-volume center, older recipient age, and requiring ICU 
care prior to ReTx were associated with increased mortality [22]. An analysis of 107 patients 
undergoing ReTx between 1990 and 1999 in the Cardiac Transplant Research Database 
reported 56% 1-year survival [23]. In this cohort, patients undergoing ReTx for acute graft fail-
ure had 1-year survival of 50%, and in patients with acute rejection 1-year survival was even 
lower at 32% [23]. However, they found that retransplantation for CAV was associated with 
better survival with improvements in survival over time [23]. In the most recent analysis of 
the ISHLT database, patients undergoing ReTx between 2006 and June 2013 had one-year sur-
vival of 70%, but patients undergoing ReTx for primary graft failure had a one-year survival 
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of 46% [9]. By comparison, patients undergoing ReTx for CAV had a one-year survival of 74% 
[23]. These studies highlight the importance of considering the indication for ReTx, which is a 
consistent predictor of mortality after correcting for other patient factors.
4.3. Outcomes in the pediatric population
Survival after ReTx is also strongly influenced by the age of the recipient. Therefore, authors 
have suspected that survival in the pediatric population may be better compared to adult pop-
ulations. Select studies are outlined in Table 3. Razzouk et al. reported a cohort of 12 pediatric 
patients undergoing ReTx between 1985 and 1997 [24]. They found similar 1-year survival 
in patients undergoing ReTx compared to patients undergoing initial cardiac transplant [24]. 
Dearani et al. reported an updated cohort from the same center including 22 patients who 
underwent ReTx before 1999 [25]. One-year and 3-year survival was numerically, but not statis-
tically, superior compared to initial transplant patients, with 3-year survival of 81.9 compared 
to 77.3% [25]. A cohort of 26 pediatric ReTx patients from Denver had similar one-year survival 
of 83% [26]. Conway et al. identified patients who underwent initial cardiac transplantation 
before age 18 in the ISHLT database [7]. They identified 602 patients who underwent ReTx 
between 1988 and 2010 and found that early mortality was similar to patients undergoing ini-
tial cardiac transplant, with a hazard ratio of only 1.07 [7]. However, patients undergoing ReTx 
were more likely to develop CAV, late rejection, and late renal dysfunction [7]. An important 
consideration in this group is that pediatric patients who are listed on adult transplant wait-
lists will wait for a longer period of time and are more likely to die on the waitlist [27]. Given 
Author Year Registry Patients Results
Srivasta 2000 ISHLT 514 patients (155 acute, 359 
chronic)
1-year survival 65%, 3-year survival 55%
Radovancevic 2002 CTRD 107 patients (49 acute, 58 chronic) 1-year survival 56%, 5-year survival 38%
Lund 2014 ISHLT 820 patients (77% chronic, 23% 
acute)
1-year survival 70%, 5-year survival 54%
Table 2. Registry studies of re-transplant survival.
Author Year Center/registry Patients Results
Razzouk 1998 Loma Linda 12 patients 1-year survival 84.3 (vs. 83.3%), 4-year survival 
74.4 (vs 83.3%)
Dearani 2001 Loma Linda 22 (16 chronic, 6 
acute)
1-year survival 81.9% (vs 84.1%), 3-year 
survival 81.9% (vs 77.3%)
Karamichalis 2011 Denver 26 (10 chronic, 16 
acute)
1-year survival 83%, 5-year survival 67%
Conway 2014 ISHLT 602 (acute and 
chronic)
1-year survival 83%, 5-year survival 69%
Table 3. Pediatric studies of re-transplant survival.
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the improved proportional survival of pediatric ReTx patients compared to adult cohorts, it is 
likely that outcomes will also be acceptable in the younger adult population.
5. Patient selection for cardiac re-transplantation
The Consensus Conference on Retransplantation was sponsored by the American Society of 
Transplantation, the American Society of Transplant Surgeons, and the National Institute of 
Allergy and Infectious Diseases and was held in Atlanta in 2006 and outlined several impor-
tant considerations for ReTx candidacy [6]. The working group concluded that patients 
undergoing ReTx should have either chronic graft failure in the absence of active rejection, 
or severe CAV not amenable to medical or surgical therapy. Additionally they suggested 
that patients with CAV should have either symptoms attributable to CAV or moderate to 
severe left ventricular dysfunction. Additionally, they proposed that patients with graft fail-
ure due to ongoing acute rejection, especially less than 6 months post-transplant, be ineli-
gible for ReTx. In addition to considerations regarding the indication for ReTx, there are 
several other patient factors that warrant discussion given their strong associations with 
survival following ReTx.
Patient selection is a key component for improving short and long-term survival following 
ReTx. A summary of factors known to be associated with patient outcomes is presented in 
Table 4. Long-term survival is strongly driven by age at time of ReTx, as evidenced by rela-
tively good outcomes seen in pediatric populations. Given the impact of age on survival, 
some groups have questioned the efficacy of ReTx in patients over the age of 60 years [6]. 
Patients undergoing ReTx have longer exposure to immunosuppression which may explain 
a possible increase in the risk of infections and malignancies; [28] therefore, careful attention 
should be given to excluding infection or occult malignancy when assessing ReTx candidacy. 
Poor renal function is also more common in ReTx patients and is associated with increased 
mortality. In a cohort of ReTx patients from Stanford, patients with creatinine >2.0 mg/dL 
had worse short-term outcomes, while patients undergoing simultaneous heart and kidney 
transplant had improved survival [14]. Similarly, patients on hemodialysis undergoing initial 
cardiac transplant in the UNOS database had better survival when undergoing simultaneous 
Associated with worse patient outcomes Associated with improved patient outcomes
Shorter interval between initial transplant and ReTx (<6 months) Younger age
Primary/acute graft failure Lack of peripheral vascular disease
Ischemic cardiomyopathy CAV/Chronic graft failure
Renal dysfunction (Creatinine >2.0 mg/dL)
Multiple previous sternotomies
Requiring ICU care pre-operatively
Table 4. Summary of predictors associated with patient outcomes.
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heart-kidney transplant compared heart transplant alone [29]. Therefore, poor renal function 
should be considered a relative contraindication to ReTx unless the patient is a candidate for 
simultaneous heart-kidney transplant.
The number of previous sternotomies should also be considered when deciding if a patient is 
a candidate for ReTx. Multiple previous sternotomies from prior palliative congenital proce-
dures or coronary artery bypass grafting adds to the burden of scar tissue, in addition to poten-
tially complicated anastamotic sites from the initial transplant. Some authors have argued that 
this contributes to the high rates of multi-system organ failure in patients after ReTx, as well as 
high rates of early mortality [18, 28]. These findings are attributed to an increased incidence of 
mediastinitis, intrathoracic bleeding requiring reintervention, and primary graft failure [30]. 
These findings have also been seen in pediatric ReTx, many of which have had previous pal-
liative procedures [26]. Lastly, patients admitted to ICU prior to ReTx, and particularly those 
requiring mechanical circulatory support, have worse outcomes [31]. In these patients it is 
important to not only ensure that organ dysfunction is reversible, but also that the patient will 
be capable of undergoing rehabilitation if the operation is successful. Consideration of these 
factors may help identify patients with the greatest potential benefit from ReTx.
Patients undergoing ReTx are more highly sensitized than patients undergoing initial car-
diac transplant [5]. Higher sensitization increases the risk of CAV, acute rejection and post-
transplant mortality [32, 33]. Therefore, it may be necessary to consider options to desensitize 
patients prior to ReTx in order to improve the chance of successful graft matching as well as 
improving outcomes following ReTx.
6. Management of patients following re-transplantation
Many studies have highlighted the high early mortality seen after ReTx and patient factors 
that might be driving this observation. This may reflect the increased complexity of the surgi-
cal operation as well as medical frailty in patients undergoing ReTx, but highlights the impor-
tance of careful early management. As mentioned previously, the most important aspect 
of patient management is careful selection of patients who are likely to benefit from ReTx. 
However, once an appropriate patient has been selected, it is important to optimize the peri-
operative care in order to attain the best possible outcomes.
From a surgical perspective, it is important to identify the surgical technique used in the ini-
tial transplant. It may be especially pertinent to determine if the patient underwent bicaval or 
bi-atrial anastomosis as well as the level of anastomosis of the pulmonary artery and aorta. 
Dedicated thoracic imaging, either computed tomographic or magnetic resonance, may help 
identify anastomotic sites and areas with significant fibrotic tissue. It is not clear if it is necessary 
to completely excise all of the tissue from the initial cardiac transplant and no guidelines exist to 
advise clinical practice. Theoretically, it may help to reduce the potential for immunogenicity in 
those patients; however, this benefit needs to be weighed against increasing the complexity of 
the operation, which could potentially prolong bypass time and increase peri-operative compli-
cations. Finally, careful attention to hemostasis is important as always, but may be particularly 
important in ReTx patients in whom peri-operative bleeding is more frequent.
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There are no clear guidelines on the post-operative care for patients undergoing ReTx. 
Theoretically, it may not be necessary to add induction therapy if patients have been main-
tained on high doses of immunosuppression, since their immune response is already sig-
nificantly blunted. This is not the case for patients undergoing ReTx for refractory rejection 
or patients who are highly sensitized. However, most transplant centers have used similar 
induction and immunosuppressive regimens for their primary transplant and ReTx patients. 
Following induction, it may be reasonable to de-escalate immunosuppression more quickly 
than would be typical after initial transplantation in order to reduce the long-term risks asso-
ciated with malignancy and infection.
7. Alternative therapies
Unfortunately, there are no established alternatives to ReTx for patients who have developed 
late complications of cardiac transplantation. There are no effective strategies for managing 
end-stage CAV and mortality rates are very high. Similarly, there are no established medical 
therapies for patients who have developed late graft dysfunction. Columbia has reported 
the use of mechanical circulatory support as a bridge to re-transplantation [34]. However, 
given the prevalence of restrictive filling dynamics and right ventricular dysfunction, long-
term mechanical support is unlikely to be successful in many patients. Therefore, there are no 
clearly viable alternatives to ReTx and the default therapy has been, and will continue to be, 
palliative care. Therefore, it is important to review end-of-life planning and consider pallia-
tive care consultation in patients who develop long-term complications.
8. Ethical considerations in re-transplantation
A complete discussion of the ethical considerations of ReTx beyond the scope of this chapter 
and readers would be well-served to read dedicated manuscripts [18, 35–37]. Donor hearts 
are a limited resource and need to be valued appropriately. The number of patients listed for 
cardiac transplantation greatly outstrips this supply and will continue to do so until we use a 
much larger proportion of potential donor hearts, an alternate source of grafts is established, 
or fewer patients require cardiac transplantation. None of these events are likely to occur in 
the near future. Given the ongoing scarcity of donor hearts, it is important to offer organs to 
those patients who would derive the most benefit. This is a strong argument against ReTx 
for acute indications, where outcomes are consistently poor. ReTx for CAV or chronic graft 
dysfunction is also associated with worse survival compared to initial transplantation, but 
it is not clear if this is a sufficient reason to exclude all ReTx. Finally, there has been concern 
regarding the possible injustice inherent in ReTx. Many patients will not survive to receive 
a single heart transplant and it may not seem equitable for a single patient to receive two, or 
even three organs when there are patients who die before receiving their first. This debate will 
continue, but if clinical outcomes continue to improve in ReTx populations, there may be a 
shift towards broader acceptance of this procedure.
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9. Conclusions
ReTx represents a small proportion of heart transplant procedures today; however, survival 
following cardiac transplantation has improved dramatically and more patients are surviving 
until they develop late complications such as CAV or graft failure. ReTx is the only therapy 
that offers meaningful improvement in survival to these patients. Survival after ReTx seems 
to be reduced, but may be acceptable in appropriately chosen patients. Tailored surgical and 
post-operative care is critical to improving patient outcomes in those accepted for ReTx.
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